MorphoSys AG (Frankfurt Stock Exchange: MOR; Prime Standard Segment) announced that the Company's shareholders approved a three-for-one split of the Company's common stock at the Company's Annual Shareholder Meeting today. Each shareholder will receive two additional shares for every outstanding share held on a given record date, and trading will begin on a split-adjusted basis in July 2007.

 

As part of the shareholder assembly agenda, the shareholders also confirmed the appointment of Dr. Walter Blättler, formerly Executive Vice President, Science and Technology of ImmunoGen, Inc., to the MorphoSys Supervisory Board. Dr. Blättler replaces Prof. Dr. Andreas Plückthun, Professor of Biochemistry, University of Zurich and co-founder of MorphoSys AG.

 

Prof. Plückthun co-founded the Company in 1992 and served on the board since that time. He is leaving the board at his own request, in order to devote additional time to his increasing number of academic research programs at the University of Zurich, as well as to be able to pursue other entrepreneurial opportunities.

 

All other management proposals of the shareholder assembly agenda were passed with large majorities at the meeting in Munich.

 

'We are pleased to announce Dr. Blättler's formal appointment to our Supervisory board. On behalf of the company, I would like to thank Professor Plückthun for his efforts in helping us to establish MorphoSys as one of the leading antibody companies in the world,' commented Dr. Simon Moroney, Chief Executive Officer of MorphoSys AG.

 

'Today's announced stock split reflects our optimism in the growth prospects of MorphoSys,' remarked Dave Lemus, Chief Financial Officer of MorphoSys AG. 'The resulting increased liquidity of MorphoSys's shares will support our efforts to broaden our shareholder base as it offers potential benefits for both private and institutional investors.'